FDA Approves ZymoGenetics’ RECOTHROMTM Thrombin, Topical (Recombinant)

ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that the United States Food and Drug Administration (FDA) has approved RECOTHROMTM Thrombin, topical (Recombinant) for sale. RECOTHROM, previously referred to as recombinant thrombin (rThrombin), is the first and only recombinant, plasma-free thrombin approved for use as a topical hemostat.

More: continued here

Filed under: Blood on January 29th, 2008